|
The Crystalens implant, which was first FDA approved in 2003, continues today
to grow in popularity even over more recently released multifocal lens implant
technologies. This increase in popularity is partly because, unlike other multifocal
implants, the Crystalens has undergone continuous redesign and improvement
since its approval.
Each redesign of the Crystalens has resulted in better
depth of focus and quality of vision for patients. Harvard Eye Associates is
one of four centers in the US undertaking a trial seeking FDA approval of the
newest, fourth generation Crystalens, called the HD-100.
This lens is not new;
it has been in regular use in the Dominican Republic, where American-trained
surgeons have performed hundreds of implants. Studies on these patients have
shown the fourth generation lens to provide even greater focus for near vision
than the third generation lens in current use in the US.
You may be eligible to participate if you:
-
are at least 50 yrs of age
- have a cataract in need of surgery
- do not have any serious eye diseases
- are not taking medicines for diabetes
- have not had previous surgery in that eye
|